Kardigan, Inc. (Ticker: KARD US) is an American late-stage biotechnology company incorporated in Delaware and focused on precision cardiovascular therapies. The company is advancing three clinical programs: danicamtiv for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen for acute severe hypertension post-hospitalization. Kardigan also operates Prolaio, a proprietary data and analytics platform using wearable sensors and AI-driven analytics to support clinical trials and digital clinical endpoints.

Kardigan plans to list on the NASDAQ on June 18, 2026. According to published terms, the company plans to offer 23.33 million shares at a price range of $14.00 to $16.00 per share, raising approximately $350 million at the midpoint. The estimated market capitalization is approximately $1.3 billion.

For the 12 months ended March 31, 2026, Kardigan reported no product revenue and a net loss of approximately $230 million. The company was founded in 2023 and had 241 employees. J.P. Morgan, Jefferies, Leerink Partners and TD Cowen are serving as joint bookrunners.